Skip to main content

Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy

Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established.

METHODS

We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo.

RESULTS

The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients without diabetes (464.0 vs. 36.5 mIU per milliliter, P<0.001). The median VEGF level in patients with retinopathy was also significantly higher than that in patients without diabetes (345.0 vs. 3.9 pg per milliliter, P<0.001). Multivariate logistic-regression analyses indicated that erythropoietin and VEGF were independently associated with proliferative diabetic retinopathy and that erythropoietin was more strongly associated with the presence of proliferative diabetic retinopathy than was VEGF. Erythropoietin and VEGF gene-expression levels are up-regulated in the murine ischemic retina, and the blockade of erythropoietin inhibits retinal neovascularization in vivo and endothelial-cell proliferation in the vitreous of patients with diabetic retinopathy in vitro.

CONCLUSIONS

Our data suggest that erythropoietin is a potent ischemia-induced angiogenic factor that acts independently of VEGF during retinal angiogenesis in proliferative diabetic retinopathy.

Article:-

Pathologic growth of new blood vessels is a common final pathway in ocular neovascular diseases, such as proliferative diabetic retinopathy, that often result in catastrophic loss of vision. Vascular endothelial growth factor (VEGF) is a primary angiogenic factor that mediates such ischemia-induced retinal neovascularization. VEGF levels are elevated in the vitreous fluid of patients with proliferative diabetic retinopathy, and VEGF induces proliferation in vascular endothelial cells in vitro.1 Although inhibition of VEGF reduces retinal neovascularization,2,3 it does not completely inhibit ischemia-driven retinal neovascularization. Thus, the involvement of other angiogenic factors in this process seems likely.

The glycoprotein erythropoietin stimulates the formation of red cells by enhancing both their proliferation and their differentiation and by preventing apoptotic death of erythropoietin-responsive erythroid precursor cells.4-6 A major signal that regulates the production of erythropoietin in these tissues is hypoxia, and the brain has a paracrine system involving erythropoietin and erythropoietin receptors, suggesting that erythropoietin contributes to the survival of neurons by protecting them from ischemic damage.7-9 Furthermore, erythropoietin shows angiogenic activity in vascular endothelial cells, stimulating proliferation, migration, and angiogenesis in vitro, probably by means of the erythropoietin receptor expressed in those cells.10,11 Such angiogenic activity involves several signal-transduction cascades such as extracellular signal-regulated kinase, Janus kinase 2 (known as JAK2), and signal transducer and activator of transcription 5 (STAT5).12-15 Moreover, the inhibition of erythropoietin by soluble erythropoietin receptor abrogates angiogenesis in vivo.16,17

Since erythropoietin is an ischemia-induced paracrine factor that promotes angiogenesis, we wished to identify its potential role during retinal angiogenesis in proliferative diabetic retinopathy. Therefore, we examined in vitro the expression and function of erythropoietin in the vitreous fluid of patients with proliferative diabetic retinopathy and evaluated the role of erythropoietin in an in vivo experimental model of retinal angiogenesis. Our data provide strong evidence that erythropoietin is a potent retinal angiogenic factor independent of VEGF and is capable of stimulating ischemia-induced retinal angiogenesis in proliferative diabetic retinopathy.



Daisuke Watanabe, M.D., Ph.D., Kiyoshi Suzuma, M.D., Ph.D., Shigeyuki Matsui, Ph.D., Masafumi Kurimoto, M.D., Junichi Kiryu, M.D., Ph.D., Mihori Kita, M.D., Ph.D., Izumi Suzuma, M.D., Ph.D., Hirokazu Ohashi, M.D., Ph.D., Tomonari Ojima, M.D., Tomoaki Murakami, M.D., Toshihiro Kobayashi, Ph.D., Seiji Masuda, Ph.D., Masaya Nagao, Ph.D., Nagahisa Yoshimura, M.D., Ph.D., and Hitoshi Takagi, M.D., Ph.D.
Hide
August 25, 2005
N Engl J Med 2005; 353:782-792

www.nejm.com

Comments

Post a Comment

Popular posts from this blog

Artificial pancreas ... an option

Coming Soon: 'Artificial Pancreas' Options for Diabetes Miriam E Tucker June 20, 2016   NEW ORLEANS — Nearly closed-loop systems (also referred to as an "artificial pancreas") for improving glycemic control and minimizing hypoglycemia in type 1 diabetes are advancing rapidly, including iterations that deliver insulin alone, insulin with glucagon, or glucagon alone. Findings for several of the products in development demonstrating improvements in glycemic control and reductions in hypoglycemia were presented here at the  American Diabetes Association (ADA) 2016 Scientific Sessions . "Some people may do well on insulin only, while others may need glucagon," Vincent Crabtree, PhD, director of the artificial pancreas program at JDRF, in New York, told  Medscape Medical News , adding, "JDRF would like people to have choice, and we'd like all to be covered [by payers]." The insulin-only hybrid closed-loop 670G system (Medtronic MiniMed) is the...
Post a Comment
Read more

Protein in human blood platelets points to a new weapon against malaria

One of the world's most devastating diseases is   malaria , responsible for at least a million deaths annually, despite global efforts to combat it. Researchers from the Perelman School of Medicine at the University of Pennsylvania, working with collaborators from Drexel University, The Children's Hospital of Philadelphia, and Johns Hopkins University, have identified a protein in human blood platelets that points to a powerful new weapon against the disease. Their work was published in this months' issue of Cell Host and Microbe. Malaria is caused by parasitic microorganisms of the Plasmodium genus, which infect red blood cells. Recent research at other universities showed that blood platelets can bind to infected red blood cells and kill the parasite, but the exact mechanism was unclear. The investigators on the Cell Host and Microbe paper hypothesized that it might involve host defense peptides (HDP) secreted by the platelets. "We eventually found that a single...
Post a Comment
Read more

Do you know that ??

Dear Readers, do you know about risk factors of Lung cancer ? If you are residing in a city where polution is a great problem, like air pollution, then you be attacked by lung cancer. Also if you are a regular smoker then you are in great risk. Researches shows that only inhaling toxic smokes are not important. If you are containing " Genes " that causes lung cancer then you are in great risks. So, it is proved clinicaly that if you dont have a lung cancer gene then you may not attacked by lung cancer though you are a smoker or anything like this. But, the problem is we dont know that whether we have the gene responsible for lung cancer or not. So, it will better to quit smoking if you are a smoker. Also, clinicaly doctors get those poatients who have alredy developed a cancer after exposing to the risk factors for several years. So, if a person quits smoking even after 15years he will get rid from lung cancer. But, he must in a great risk.
Post a Comment
Read more